Anebulo Pharmaceuticals Announces Voluntary Delisting Plan
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 06 2026
0mins
Should l Buy ANEB?
Anebulo Pharmaceuticals announced that the company's board of directors has approved the voluntary delisting of the company's common stock from the Nasdaq Capital Market and the subsequent voluntary deregistration of its common stock with the SEC. Simultaneously with this announcement, Anebulo notified Nasdaq today of its intention to voluntarily delist its shares of common stock from Nasdaq. The company is in compliance with applicable Nasdaq listing requirements, but the board believes that the cost of being an SEC reporting company outweighs the benefits. As the company continues with its efforts to maximize value from its lead product candidate, the board has determined that the burdens associated with operating as a registered public company listed on Nasdaq outweigh any advantages to the company and the holders of its common stock.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ANEB?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ANEB
About ANEB
Anebulo Pharmaceuticals, Inc. is a clinical-stage biotechnology company. It is engaged in developing treatments for cannabis toxicity, such as unintentional cannabis poisoning, acute cannabinoid intoxication (ACI) and the landscape of acute cannabis-induced conditions. Its lead product candidate is selonabant, a potent, small molecule antagonist of cannabinoid binding receptor type-1 (CB1), the primary receptor involved in the psychotropic effects of cannabinoids, with the potential to address the unmet medical need for a therapy to treat cannabis toxicity. Selonabant is orally bioavailable, rapidly absorbed, and has also been formulated for intravenous administration. Selonabant is intended to rapidly reverse the negative effects of cannabis-induced toxicity and reduce time to recovery. It is also prioritizing the advancement of a selonabant intravenous (IV) formulation as a potential treatment for pediatric patients with cannabis-induced CNS depression.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Anebulo Pharmaceuticals Reports Q2 Fiscal 2026 Financial Results
- Financial Overview: Anebulo Pharmaceuticals reported a GAAP EPS of -$0.05 for Q2 of fiscal 2026, indicating ongoing challenges in profitability that may affect investor confidence.
- Stable Operating Expenses: Total operating expenses for the second quarter were $2.6 million, unchanged from the same period in fiscal 2025, suggesting the company has maintained cost control despite a lack of significant revenue growth.
- Cash Position: As of December 31, 2025, the company had $9.0 million in cash and cash equivalents, reflecting a reasonable liquidity position, but future funding needs remain a concern.
- Loan Agreement Support: The company has access to an additional $3.0 million in cash through a loan agreement, providing financial support for future operations and R&D, which may help accelerate product development.
See More
Anebulo Pharmaceuticals Announces Voluntary Delisting from Nasdaq
- Voluntary Delisting Decision: Anebulo Pharmaceuticals has announced its intention to voluntarily delist from Nasdaq, effective February 27, 2026, aiming to terminate its reporting obligations with the SEC, which is expected to significantly reduce operational costs.
- Cost-Benefit Analysis: The Board believes that the legal, audit, and management costs associated with being a public company outweigh the benefits, particularly regarding the expenses related to preparing and filing periodic reports, indicating a strategic reassessment of resource allocation.
- Shareholder Impact: Following the delisting, trading of Anebulo's stock will be limited to privately negotiated sales or the over-the-counter market, which may affect liquidity and shareholder investment options, especially given the current shareholder count is below 300.
- Product Development Priority: The company will prioritize the intravenous formulation of selonabant for pediatric patients over the adult oral product, which is expected to accelerate the clinical trial process and enhance market competitiveness.
See More
Anebulo Completes Voluntary Tender Offer for 300,000 Shares
- Tender Offer Results: Anebulo Pharmaceuticals announced the final results of its voluntary tender offer to repurchase 300,000 shares at $3.50 each, totaling approximately $1.05 million, reflecting the company's commitment to shareholders and a significant premium over market prices.
- Oversubscription: The tender offer received a total of 4,907,881 shares tendered, indicating strong investor confidence in the company's future, with 300,000 shares accepted on a pro-rata basis, ensuring benefits for smaller shareholders.
- Shareholder Structure Optimization: By executing this tender offer, Anebulo successfully reduced the number of shareholders, enhancing shareholder concentration, which may facilitate future capital operations and corporate governance.
- Clinical Research Advancement: Anebulo is prioritizing the intravenous formulation of selonabant for pediatric acute cannabis-induced toxicity treatment, aiming for a faster approval timeline, demonstrating the company's strategic shift in drug development.
See More
UniFirst Corp (UNF) Receives $5.2B Acquisition Proposal from Cintas (CTAS) at 64% Premium
- Acquisition Proposal: Cintas Corporation has proposed to acquire UniFirst for $275 per share in cash, valuing the company at approximately $5.2 billion, which represents a 64% premium over its 90-day average closing price, indicating strong confidence in UniFirst's future growth potential.
- Market Reaction: This news has driven UniFirst's stock price up by 18.6%, reflecting investor optimism regarding the acquisition deal, and it may also attract interest from other potential buyers, further intensifying market competition.
- Industry Impact: The acquisition proposal could reshape the uniform and workwear industry landscape, as Cintas aims to enhance its market share and service capabilities by integrating UniFirst's resources and customer base.
- Strategic Significance: Cintas's acquisition intent not only underscores its focus on industry consolidation but also has the potential to achieve long-term business growth and profitability enhancement through an expanded product line and service offerings.
See More
U.S. Stocks Rise with Nasdaq Gaining Over 100 Points
- Market Performance: U.S. stocks broadly rose on Monday, with the Nasdaq gaining over 100 points, indicating optimistic market sentiment towards economic recovery, which may attract more investor interest in tech stocks.
- Dow Jones Index: The Dow Jones increased by 0.18% to 48,222.17 points, reflecting stability in traditional sectors and potentially providing investors with safer investment options.
- Energy Sector Surge: Energy shares rose by 1.3%, suggesting improved expectations for energy demand, which could drive profitability growth for related companies.
- Chicago Fed National Activity Index: The index improved from -0.31 in August to -0.21 in September, indicating a slight uptick in economic activity, which may provide policymakers with justification for further economic stimulus.
See More
Biotech Stocks Rise in After-Hours Trading Driven by Data Expectations and Momentum Buying
Biotech Market Gains: After-hours trading on Wednesday saw significant gains in small-cap and micro-cap biotech stocks, driven by a mix of upcoming clinical milestones and a general positive sentiment in the market following the Fed's rate cut.
Agape ATP Corp. Surge: Agape ATP Corp. experienced a notable 29.41% increase in after-hours trading, attributed to a broader risk-on reaction in micro-cap stocks, despite no specific news from the company.
Corbus Pharmaceuticals Update: Corbus Pharmaceuticals saw a 12.76% rise ahead of a key clinical update regarding its Phase 1a study of CRB-913, with anticipation around the upcoming data likely fueling investor interest.
Other Notable Movers: Companies like Anebulo Pharmaceuticals, Cue Biopharma, and Curis also reported gains in after-hours trading, reflecting a broader recovery in biotech sentiment, while Cerus Corporation continued its upward trend following a new purchasing agreement.
See More
Anebulo Pharmaceuticals Reports Q2 Fiscal 2026 Financial Results
- Financial Overview: Anebulo Pharmaceuticals reported a GAAP EPS of -$0.05 for Q2 of fiscal 2026, indicating ongoing challenges in profitability that may affect investor confidence.
- Stable Operating Expenses: Total operating expenses for the second quarter were $2.6 million, unchanged from the same period in fiscal 2025, suggesting the company has maintained cost control despite a lack of significant revenue growth.
- Cash Position: As of December 31, 2025, the company had $9.0 million in cash and cash equivalents, reflecting a reasonable liquidity position, but future funding needs remain a concern.
- Loan Agreement Support: The company has access to an additional $3.0 million in cash through a loan agreement, providing financial support for future operations and R&D, which may help accelerate product development.
See More
Anebulo Pharmaceuticals Announces Voluntary Delisting from Nasdaq
- Voluntary Delisting Decision: Anebulo Pharmaceuticals has announced its intention to voluntarily delist from Nasdaq, effective February 27, 2026, aiming to terminate its reporting obligations with the SEC, which is expected to significantly reduce operational costs.
- Cost-Benefit Analysis: The Board believes that the legal, audit, and management costs associated with being a public company outweigh the benefits, particularly regarding the expenses related to preparing and filing periodic reports, indicating a strategic reassessment of resource allocation.
- Shareholder Impact: Following the delisting, trading of Anebulo's stock will be limited to privately negotiated sales or the over-the-counter market, which may affect liquidity and shareholder investment options, especially given the current shareholder count is below 300.
- Product Development Priority: The company will prioritize the intravenous formulation of selonabant for pediatric patients over the adult oral product, which is expected to accelerate the clinical trial process and enhance market competitiveness.
See More
Anebulo Completes Voluntary Tender Offer for 300,000 Shares
- Tender Offer Results: Anebulo Pharmaceuticals announced the final results of its voluntary tender offer to repurchase 300,000 shares at $3.50 each, totaling approximately $1.05 million, reflecting the company's commitment to shareholders and a significant premium over market prices.
- Oversubscription: The tender offer received a total of 4,907,881 shares tendered, indicating strong investor confidence in the company's future, with 300,000 shares accepted on a pro-rata basis, ensuring benefits for smaller shareholders.
- Shareholder Structure Optimization: By executing this tender offer, Anebulo successfully reduced the number of shareholders, enhancing shareholder concentration, which may facilitate future capital operations and corporate governance.
- Clinical Research Advancement: Anebulo is prioritizing the intravenous formulation of selonabant for pediatric acute cannabis-induced toxicity treatment, aiming for a faster approval timeline, demonstrating the company's strategic shift in drug development.
See More
UniFirst Corp (UNF) Receives $5.2B Acquisition Proposal from Cintas (CTAS) at 64% Premium
- Acquisition Proposal: Cintas Corporation has proposed to acquire UniFirst for $275 per share in cash, valuing the company at approximately $5.2 billion, which represents a 64% premium over its 90-day average closing price, indicating strong confidence in UniFirst's future growth potential.
- Market Reaction: This news has driven UniFirst's stock price up by 18.6%, reflecting investor optimism regarding the acquisition deal, and it may also attract interest from other potential buyers, further intensifying market competition.
- Industry Impact: The acquisition proposal could reshape the uniform and workwear industry landscape, as Cintas aims to enhance its market share and service capabilities by integrating UniFirst's resources and customer base.
- Strategic Significance: Cintas's acquisition intent not only underscores its focus on industry consolidation but also has the potential to achieve long-term business growth and profitability enhancement through an expanded product line and service offerings.
See More
U.S. Stocks Rise with Nasdaq Gaining Over 100 Points
- Market Performance: U.S. stocks broadly rose on Monday, with the Nasdaq gaining over 100 points, indicating optimistic market sentiment towards economic recovery, which may attract more investor interest in tech stocks.
- Dow Jones Index: The Dow Jones increased by 0.18% to 48,222.17 points, reflecting stability in traditional sectors and potentially providing investors with safer investment options.
- Energy Sector Surge: Energy shares rose by 1.3%, suggesting improved expectations for energy demand, which could drive profitability growth for related companies.
- Chicago Fed National Activity Index: The index improved from -0.31 in August to -0.21 in September, indicating a slight uptick in economic activity, which may provide policymakers with justification for further economic stimulus.
See More
Biotech Stocks Rise in After-Hours Trading Driven by Data Expectations and Momentum Buying
Biotech Market Gains: After-hours trading on Wednesday saw significant gains in small-cap and micro-cap biotech stocks, driven by a mix of upcoming clinical milestones and a general positive sentiment in the market following the Fed's rate cut.
Agape ATP Corp. Surge: Agape ATP Corp. experienced a notable 29.41% increase in after-hours trading, attributed to a broader risk-on reaction in micro-cap stocks, despite no specific news from the company.
Corbus Pharmaceuticals Update: Corbus Pharmaceuticals saw a 12.76% rise ahead of a key clinical update regarding its Phase 1a study of CRB-913, with anticipation around the upcoming data likely fueling investor interest.
Other Notable Movers: Companies like Anebulo Pharmaceuticals, Cue Biopharma, and Curis also reported gains in after-hours trading, reflecting a broader recovery in biotech sentiment, while Cerus Corporation continued its upward trend following a new purchasing agreement.
See More
